Buy Discounted Cash, Get Patents free?Crescita has no chance of any revenue anytime soon. What it does have is cash, pipeline drugs and several fresh patents. Terbinafine and ibufoam have decent development potential albeit several years away from market. I have zero faith in Flexicaine...messy and difficult to apply and takes time to set/dry, it also requires temperature control for maintaining proper viscosity...not practical at all. Having said all of this, its the cash component that makes this an interest speculative investment at $1.50/share. Seems that $1.40 is the bottom resistance so it seems like a decent strategy to move swithch holdings of NRI into CTX up to about $2.00 per share. CTX could be more of a multiple maker than NRI from these levels. Management, if they can be trusted, insists that cash conservation is the current strategy. If a company like GUD would put an offer in at twice the current share price they would immediately be enrished with a 5mm profit and free drug pipeline...interesting thought on this icy holy thursday.
Cheers,
Schaff